EP1592690A1 — Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands

USPTO Abstract

The present invention provides a compound of formula (I) and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor. Wherein W is N or CR2; X is N or CR4; Y is N or CR5; Z is N or CR6; Q is N or CR7 with the proviso that at least one and not more than two of X, Y, Z and Q must be N: R4, R5, R6 and R7 are each independently H, halogen, CN, COR8, OCO2R9, CO2R10, CONR11R12, SOnR13, NR14R15, OR16 or C1-C6alkyl, C3-C7cycloalkyl, aryl or heteroaryl group each optionally substituted or a group M having the structure of formula (II) with the proviso that at least one of R4, R5, R6 and R7 must be a group M and with the further proviso that when W is CR2 and X or Z is N, the R7 must be other than a group M.